We are a law firm, based in Mumbai.

Phone: 9004523497 | Email: info@ynzgroup.co.in

A Bitter Dose for Pharma Compliance

Introduction[1]:

India, now also referred to as the “Pharmacy of the World,” has emerged as a global pharmaceutical powerhouse supplying to global vaccine demand and exporting affordable generic medicines to several countries. With an industry valued at over USD 49.78 billion in 2023[2], India’s drug manufacturing ecosystem has become eminent to both domestic healthcare and international markets that rely on its low-cost/cost-effective, high-quality generics.

However, this position of strength also carries a great responsibility to uphold high quality control in manufacturing and testing, ensuring patient safety, and maintaining global trust in Indian medicines. The recent tragedy in Madhya Pradesh, where 24 children lost their lives after consuming a cough syrup ‘Coldrif’, prescribed by local doctor Praveen Soni serves as a significant reminder of what happens when pharmaceutical ethics and regulatory vigilance are overlooked. This article examines the key legal breaches involved, the liabilities arising from it, and the larger compliance failures that caused this tragedy.

This tragedy has led to questions about the compliance culture within India’s drug manufacturing sector under the Drugs and Cosmetics Act, 1940. However, who will restore the joy of those unfortunate families who lost their children due to this negligence?

Layers of Accountability
  1. Under the Drugs and Cosmetics Act, 1940: The lapses herein primarily fall under the ambit of The drugs and cosmetics Act 1940. This Act governs manufacture, sale, and distribution of drugs and Section18(a)(i) prohibits any person from manufacturing or selling a drug that is not of standard quality or is adulterated or spurious. Breach of this provision attracts legal consequences under Section 27(a) of severe imprisonment of not less than 10 years, which may extend to life and shall also be liable to fine which shall not be less than ten lakh rupees or three times value of the drugs confiscated, whichever is more.
  2. Manufacturing Non-Compliance and GMP Violations:
    Under the Drugs and Cosmetics Rules, 1945[4], Rule 71 contains conditions for grant and    renewal of license. Rule 71 (7) states that every licensed manufacturer must adhere to Good      Manufacturing  Practices (GMP) prescribed in Schedule M. These include strict protocols for:
    • Sanitation: The manufacturing premises shall be cleaned and maintained in an orderly manner, so that it is free from accumulated waste, dust, debris and other similar material.
    • Source of Raw Material: All incoming materials shall be purchased from approved sources under valid purchase vouchers. Wherever possible, raw materials should be purchased directly from the producers.
    • Testing and Quality control systems :Quality control shall be concerned with sampling, specifications, testing, documentation, release procedures which ensure that the necessary and relevant tests are actually carried and that the materials are not released for use, nor products released for sale or supply until their quality has been judged to be satisfactory. It is not confined to laboratory operations but shall be involved in all decisions concerning the quality of the product.
    • Quality Control Area: Schedule M, Part I requires quality control laboratories to be independent of the production areas. The head of the quality control laboratory shall be independent of the manufacturing unit and the testing shall be conducted under the direct supervision of competent technical staff.

Ingredients and quantity under Rule 71(6)(iv)[5] the proprietary medicine shall contain such ingredients and in such quantities for which there is therapeutic justification.

Under Rule 74(c) each batch of raw material as well as finished products must be verified for purity and quality before use.

A prominent default was that the company procured and used industrial-grade solvents and excipients instead of pharmaceutical-grade material which is a direct violation of GMP. Such failure points to gross negligence or wilful disregard of the manufacturer’s statutory obligations.

Apart from this, the drug inspector stated in their report that medicines in the unit were stored under unhygienic conditions. There was no pest control measures, purified water generation system or cleaning procedures in place. Equipment in the unit was rusty cracked and leaking.[6]

This tragedy in Madhya Pradesh serves as a stark reminder of the critical role that legal compliance and quality control play in safeguarding public health. India’s pharmaceutical sector, while globally respected, must continuously strengthen its internal checks, GMP adherence, and regulatory coordination under the Drugs and Cosmetics Act, 1940. Consistent inspections, transparent reporting, and ethical manufacturing practices are very important to preventing lapses and preserving global confidence in Indian medicines.